Drug Profile
Research programme: diabetic nephropathy therapeutics - Boehringer Ingelheim/University of Michigan
Latest Information Update: 28 Jun 2019
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; University of Michigan
- Developer Boehringer Ingelheim; National Institutes of Health (USA); University of Michigan; University of Minnesota
- Class Antihyperglycaemics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic nephropathies
Most Recent Events
- 28 Jun 2019 No recent reports of development identified for research development in Diabetic-nephropathies in USA
- 28 May 2015 Boehringer Ingelheim and the University of Michigan agree to co-develop diabetic nephropathy therapeutics
- 28 May 2015 Early research in Diabetic nephropathies in USA (unspecified route)